TheraVitae & VesCell™ Heart Therapy Acknowledged by Leading Medical Journal

TheraVitae are proud to have been recognised in the July issue of leading medical journal 'Regenerative Medicine' as being a ‘serious player in the international arena of regenerative therapy’.

In addition, the periodical states that VesCell™, TheraVitae’s treatment for heart disease, provides the best commercially available stem cell-based treatment for ‘no-option’ cardiac patients.

The full Press Release is below:

VesCell™ Stem Cell Heart Therapy Acknowledged as Best Available Commercial Treatment for No Option Cardiac Patients by Leading Medical Journal

TheraVitae Ltd, is named as being ‘a serious player in the international arena of regenerative therapy’ in July 2006 issue of ‘Regenerative Medicine’ whilst TheraVitae’s proprietary adult stem cell therapy for heart disease, VesCell™ is described as being the best commercially available stem cell-based treatment for no-option cardiac patients.

Leading stem cell research journal ‘Regenerative Medicine’ recently confirmed the achievements of TheraVitae Ltd. by naming the Israeli-Thai company as being a ‘serious player in the international arena of regenerative therapy’. The bi-monthly journal, which provides a forum to address advances in stem cell research and regenerative medicine, makes the pronouncement in an article in the July 2006 issue.

Backed by the opinions of an International Editorial Board of over 65 experts, the periodical’s July round-up of industry news goes on to conclude that VesCell™, TheraVitae’s treatment for heart disease, provides the best commercially available stem cell-based treatment for ‘no-option’ cardiac patients. These are patients afflicted by severe medical conditions that cannot be treated using conventional procedures such as bypass surgery or balloon angioplasty due to the risks associated with these options.

Patients are treated with self-derived stem cells isolated by TheraVitae’s proprietary technology. Angiogenic cell precursors harvested from the patients’ peripheral blood in Bangkok are expanded and differentiated in-vitro in a facility in Israel. The product, VesCell™, is sent back to Thailand where is injected, either directly into patient’s heart, or delivered via intracoronary catheter.

Stressing that TheraVitae’s aim is not to seek a miracle cure for heart disease but to provide sufferers a new lease on life and the chance to once again enjoy activities which they never thought possible, Dr Valentin Fulga, CEO of TheraVitae is quoted, in Regenerative Medicine’s July 2006 issue, as saying, “Depending on the disease, we follow improvement in perfusion of the ischemic region in the heart in patients with angina pectoris, or ejection fraction for patients with heart failure. However, our cardinal assessment parameters remain the general condition of the patient and improvement in his/her ability to perform regular daily tasks”.